OptiBiotix Health PLC Notice of Results (0419G)
August 03 2016 - 2:01AM
UK Regulatory
TIDMOPTI
RNS Number : 0419G
OptiBiotix Health PLC
03 August 2016
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Notice of Results
Analyst Briefing
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, will announce its interim results for the six months
ended 31 May 2016 on Thursday, 25 August 2016.
A briefing for analysts will take place at the offices of
Walbrook PR, 4 Lombard St., London EC3V 9HD at 10am on Thursday 25
August 2016.
If you would like to register to attend the briefing, or require
further information, please contact Walbrook PR on 020 7933 8780 or
email optibiotix@walbrookpr.com.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Contact via Walbrook below
Executive
Cairn Financial Advisers Tel: 020 7148 7900
LLP
Liam Murray
Hybridan LLP (Joint Broker) Tel: 0203 764 2341
Claire Louise Noyce
Peterhouse Corporate Finance Tel: 020 7469 0936
Ltd (Joint Broker)
Lucy Williams / Duncan
Vasey
Walbrook PR Ltd Tel: 020 7933 8780 or
optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFVETIIFIIR
(END) Dow Jones Newswires
August 03, 2016 02:01 ET (06:01 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Aug 2023 to Aug 2024